| 91.32 1.72 (1.92%) | 10-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 121.47 | 1-year : | 141.87 |
| Resists | First : | 104 | Second : | 121.47 |
| Pivot price | 90.49  |
|||
| Supports | First : | 58.15 | Second : | 29.8 |
| MAs | MA(5) : | 88.4 |
MA(20) : | 91.56 |
| MA(100) : | 49.62 |
MA(250) : | 37.46 |
|
| MACD | MACD : | 8 |
Signal : | 10 |
| %K %D | K(14,3) : | 43.1 |
D(3) : | 37.1 |
| RSI | RSI(14): 61.9 |
|||
| 52-week | High : | 104 | Low : | 15.82 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KOD ] has closed below upper band by 45.7%. Bollinger Bands are 10.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 94.87 - 95.25 | 95.25 - 95.65 |
| Low: | 88.3 - 88.68 | 88.68 - 89.07 |
| Close: | 90.69 - 91.36 | 91.36 - 92.05 |
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Tue, 27 Oct 2026
H.C. Wainwright lifts target for Kodiak Sciences stock to USD 126 - ad-hoc-news.de
Fri, 23 Oct 2026
Kodiak Sciences Inc Estimates – NASDAQ:KOD - TradingView
Fri, 23 Oct 2026
Kodiak Sciences Inc (KOD) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Fri, 23 Oct 2026
Kodiak Sciences (KOD) CFO John Borgeson Sells 30,000 Shares - GuruFocus
Fri, 23 Oct 2026
After exercising $2.49 options, Kodiak Sciences (KOD) CFO sells 30,000 shares. - Stock Titan
Thu, 22 Oct 2026
Kodiak Sciences Inc. (KOD) Options Chain - Yahoo Finance - Yahoo! Finance Canada
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 5.1 (%) |
| Held by Institutions | 105.5 (%) |
| Shares Short | 9,380 (K) |
| Shares Short P.Month | 10,780 (K) |
| EPS | -4.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.97 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -60.5 % |
| Return on Equity (ttm) | -368.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -159 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -21.8 |
| PEG Ratio | 0 |
| Price to Book value | 94.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -36.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|